Page 2 - Mark Neumann News Today

Privium Fund Management B.V. boosted its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 12.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 93,650 shares of the biopharmaceutical company’s stock after buying an additional 10,000 shares during the quarter. […]

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) has earned a consensus recommendation of “Buy” from the ten brokerages that are covering the firm, Marketbeat.com reports. Ten equities research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have issued a report on the stock in the […]

Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) have been assigned an average recommendation of “Buy” from the ten analysts that are currently covering the stock, Marketbeat reports. Ten analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have covered the stock in the […]

Orion Portfolio Solutions LLC lowered its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 3.7% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 27,298 shares of the biopharmaceutical company’s stock after selling 1,061 shares during the period. Orion Portfolio Solutions LLC’s holdings […]

TD Cowen started coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) in a research report sent to investors on Monday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $75.00 price target on the biopharmaceutical company’s stock. Several other brokerages have also commented on ITCI. Needham & Company LLC upped their […]

Regal Investment Advisors LLC lifted its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 39.3% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,424 shares of the biopharmaceutical company’s stock after acquiring an additional 3,789 shares during the period. […]

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) saw some unusual options trading activity on Friday. Investors purchased 2,832 call options on the company. This represents an increase of approximately 901% compared to the average daily volume of 283 call options. Analysts Set New Price Targets ITCI has been the subject of a number of […]

Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) have been assigned an average rating of “Buy” from the eight ratings firms that are presently covering the firm, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have issued a report on the […]

Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) had its price target lowered by equities researchers at Royal Bank of Canada from $77.00 to $76.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s target price would indicate a […]

Operator: Thank you for standing by, and welcome to the Intra-Cellular Therapies 3Q 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.